A gene best known for helping cells fine-tune thousands of molecular messages is drawing renewed attention in pediatric thyroid cancer. A systematic review by Anna Dimaki, E.P. Kotanidou, V.R. Tsinopoulou and colleagues examines mutations in the DICER1 gene among children and adolescents diagnosed with thyroid cancer, bringing together evidence from a field where rare genetic alterations may have consequences far beyond a single tumor. Published in Pediatric Research, the review focuses on how changes in DICER1 may intersect with thyroid tumor development, inherited cancer susceptibility and the clinical decisions faced by young patients and their families.
DICER1 is essential to the production of microRNAs, short strands of RNA that regulate gene activity after DNA has been transcribed into messenger RNA. These molecules act partly as molecular dimmers, reducing the production of particular proteins and helping control cell division, differentiation and survival. DICER1 encodes an enzyme that cuts precursor RNA molecules into mature microRNAs. When the gene is altered, the quantity or quality of these regulatory molecules can change, potentially disturbing networks that normally restrain uncontrolled growth. Because microRNAs influence many biological pathways at once, DICER1 disruption may affect several organs and produce a diverse range of tumors.
The gene is associated with DICER1 tumor predisposition syndrome, a hereditary condition in which affected individuals can develop a variety of rare neoplasms. The syndrome is typically linked to a germline alteration, meaning that the variant is present in nearly every cell from birth, followed in some tumors by an additional acquired change in the other copy of the gene. This combination is often described through a “two-hit” model of tumor development. Not every person carrying a DICER1 variant develops cancer, and the clinical picture can differ substantially between relatives. That variability makes the interpretation of genetic findings particularly important in children, whose medical histories and future risks may still be unfolding.
Thyroid cancer is uncommon in childhood compared with adulthood, but it is the most frequent endocrine malignancy in children and adolescents. Pediatric tumors can differ from adult disease in their biology, clinical presentation and relationship to inherited cancer syndromes. Many young patients have excellent outcomes, yet thyroid cancer may require surgery, radioactive iodine or long-term monitoring, depending on the tumor type and extent of spread. Identifying a genetic predisposition can add another layer to care: it may influence the evaluation of other organs, inform testing for relatives and shape discussions about surveillance. At the same time, a genetic result must be interpreted carefully so that families are not exposed to unnecessary alarm or procedures.
The systematic review addresses an important question because DICER1-associated thyroid disease has been reported across different clinical settings and may not always appear in the same form. Some cases are identified after a child develops a thyroid nodule or carcinoma, while others emerge during evaluation of a known familial predisposition. Researchers conducting a review of this kind compare findings from previously published studies, examining how DICER1 variants were detected, whether they were inherited or tumor-specific, what thyroid diagnoses were reported and how patients were managed. By assembling these scattered observations, the authors aim to clarify the strength and consistency of the available evidence.
At the molecular level, DICER1-related cancer biology is more complicated than a simple loss-of-function story. Different variants can affect distinct domains of the DICER1 protein, including regions involved in RNA processing. Some alterations reduce the overall amount of functional enzyme, whereas others may selectively interfere with the processing of particular microRNA families. This can create a characteristic imbalance in gene regulation rather than shutting down the entire pathway. In tumor cells, that imbalance may favor proliferation, alter differentiation or weaken normal responses to cellular stress. Understanding these mechanisms may eventually help researchers distinguish which variants carry meaningful cancer risk and which changes are less likely to be clinically important.
For pediatric endocrinologists and oncologists, the review’s subject has practical implications beyond the thyroid gland. A child with a pathogenic germline DICER1 variant may require a personalized surveillance strategy based on age, family history and the spectrum of tumors associated with the syndrome. Genetic counseling can help explain inheritance, testing options and the limits of current knowledge. Testing may also identify relatives who could benefit from medical follow-up, while revealing that others have not inherited the familial variant. Such decisions are especially sensitive in children because surveillance must balance early detection with the psychological, financial and medical burdens of repeated imaging and examinations.
The review also highlights why genetic studies of rare pediatric cancers can be difficult to interpret. Published reports may include small numbers of patients, different sequencing methods and inconsistent definitions of what constitutes a DICER1-associated thyroid tumor. Some studies analyze blood or saliva to search for germline variants, while others sequence tumor tissue to identify changes acquired only by cancer cells. A variant found in a tumor does not automatically indicate an inherited syndrome, and a variant detected in blood requires classification according to evidence about its biological effect and disease association. Differences in referral patterns can further complicate estimates of how often DICER1 mutations occur among young people with thyroid cancer.
For families, the most important message is that a DICER1 mutation is a risk marker, not a prediction that cancer will inevitably develop. The findings summarized by Dimaki and colleagues may help move clinical practice toward more precise assessment, but they do not eliminate the need for individualized medical judgment. Thyroid nodules in children should be evaluated according to established pediatric guidelines, and genetic testing is most informative when accompanied by professional counseling. As researchers learn more about how specific DICER1 variants alter microRNA processing, the hope is that surveillance can become more targeted and that unnecessary interventions can be reduced without missing early disease.
The study arrives at a moment when sequencing is becoming increasingly accessible in pediatric oncology. As genetic information enters routine care, systematic reviews are essential for separating robust patterns from isolated case reports and for identifying questions that future research must answer. Larger international registries, standardized variant classification and long-term follow-up could clarify the relationship between DICER1 alterations and thyroid cancer risk, tumor behavior and treatment response. For now, the review places DICER1 at the center of an evolving conversation about inherited susceptibility, RNA biology and the early detection of cancer in young people—an intersection where discoveries in molecular science may directly influence clinical care.
Subject of Research: DICER1 gene mutations and their association with thyroid cancer in children and adolescents.
Article Title: Mutations of the DICER1 gene among children and adolescents with thyroid cancer: a systematic review
Article References: Dimaki, A., Kotanidou, E.P., Tsinopoulou, V.R. et al. Mutations of the DICER1 gene among children and adolescents with thyroid cancer: a systematic review. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05334-4
Image Credits: AI Generated
DOI: 10.1038/s41390-026-05334-4
Keywords: DICER1, thyroid cancer, pediatric oncology, adolescents, children, microRNA, genetic mutations, DICER1 tumor predisposition syndrome, hereditary cancer, systematic review
